Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Immune competence after alemtuzumab treatment of multiple sclerosis.
Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.
Novantrone (mitoxantrone HCl) Injection February 2009
Glatiramer Acetate and Nanny Proteins Restrict Access of the Multiple Sclerosis Autoantigen Myelin Basic Protein to the 26S Proteasome.
Combination therapy with mitoxantrone and plasma exchange in aggressive relapsing remitting multiple sclerosis: A preliminary clinical study.
Biogen Idec submits application to FDA for approval of PLEGRIDY™ (peginterferon beta-1a) in multiple sclerosis
Adaptive myelination from fish to man.
Isolation of Clostridium perfringens Type B in an Individual at First Clinical Presentation of Multiple Sclerosis Provides Clues for Environmental Triggers of the Disease.
Genmab announces results of ofatumumab Phase II study in multiple sclerosis
Oracle Cladribine in Early Multiple Sclerisis (MS) (ORACLE MS)
One can prevent post-partum MS relapses by exclusive breast feeding: no.
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
ARESTIN®
Refining diagnosis of multiple sclerosis with revised MRI criteria.
Breastfeeding and multiple sclerosis.
Treatment of neurological injury with thymosin β4.
Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.
Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies.
Immunosuppressive properties of mesenchymal stem cells: advances and applications.
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.
Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis.
Voltage-gated potassium channels in multiple sclerosis: Overview and new implications for treatment of central nervous system inflammation and degeneration.
Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis.
Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension study.
RTL therapy for multiple sclerosis: a Phase I clinical study.

Pages